Results of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Remedy on Glucose Homeostasis and Physique Weight in Sufferers With Kind 1 Diabetes: A Community Meta-Evaluation
On this research, we aimed to judge the efficacy and security of add-on to insulin remedy in sufferers with T1D. We carried out direct and oblique community meta-analyses utilizing Bayesian fashions and ranked hypoglycemic brokers through combined remedy comparability, utilizing knowledge from the CENTRAL, MEDLINE, EMBASE, and Science Quotation Index Expanded databases.
Randomized managed trials (RCTs) involving sufferers with T1D handled with insulin and add-on metformin or sodium-glucose cotransporter inhibitors or glucagon-like peptide-1 receptor agonists from January 1970 to September 2019 have been included on this research. Twenty-three RCTs with 5,151 topics have been divided into the next teams: insulin alone, insulin+metformin, insulin+canagliflozin, insulin+dapagliflozin, insulin+empagliflozin, insulin+sotagliflozin, insulin+liraglutide, and insulin+exenatide. HbA1c degree within the insulin+sotagliflozin group was considerably decrease than that within the insulin alone group (imply distinction: -0.43, 95% credible interval: -0.62 to -0.23).
Whole each day insulin dose within the insulin+sotagliflozin group was considerably decrease than that within the insulin alone group. In contrast with that within the insulin alone group, physique weight within the teams handled with insulin+add-on canagliflozin, sotagliflozin, and exenatide was considerably decreased by 4.5, 2.8, and 5.1 kg, respectively.
Hypoglycemic episodes didn’t differ among the many teams. In sufferers with T1D, insulin+sotagliflozin decreased the HbA1c degree, each day insulin dose, and physique weight with out hypoglycemia in contrast with insulin monotherapy. Insulin+canagliflozin or insulin+exenatide was efficient in decreasing physique weight in contrast with insulin alone.
In conclusion, sotagliflozin remedy decreased not solely the HbA1c ranges and insulin dose but additionally the physique weight with out inflicting hypoglycemia in sufferers with T1D. Remedy with canagliflozin and exenatide successfully diminished physique weight in sufferers with T1D. Nevertheless, ketoacidosis related to the usage of SGLT inhibitors ought to be thought-about in these sufferers. Thus, our outcomes counsel that sotagliflozin has a excessive likelihood of being ranked first as an adjunctive remedy to insulin in sufferers with T1D.
antibodysource
FCER1A antibody |
|||
| 70R-6650 | Fitzgerald | 50 ug | 467 EUR |
|
Description: Rabbit polyclonal FCER1A antibody raised against the N terminal of FCER1A |
|||
FCER1A Antibody |
|||
| ABD6593 | Lifescience Market | 100 ug | 525.6 EUR |
FCER1A Antibody |
|||
| DF6593 | Affbiotech | 200ul | 420 EUR |
FCER1A Antibody |
|||
| DF6593-100ul | Affinity Biosciences | 100ul | 168 EUR |
|
Description: WB,IHC,IF/ICC,ELISA(peptide) |
|||
FCER1A Antibody |
|||
| DF6593-200ul | Affinity Biosciences | 200ul | 210 EUR |
|
Description: WB,IHC,IF/ICC,ELISA(peptide) |
|||
FCER1A Antibody |
|||
| 1-CSB-PA008532GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against FCER1A. Recognizes FCER1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
|||
FCER1A Antibody |
|||
| 1-CSB-PA008532LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against FCER1A. Recognizes FCER1A from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF; Recommended dilution: WB:1:2000-1:5000, IHC:1:20-1:200, IF:1:50-1:200 |
|||
FCER1A Antibody |
|||
| CAC07608-100ug | Biomatik Corporation | 100ug | 314 EUR |
FCER1A Antibody |
|||
| CAC07608-50ug | Biomatik Corporation | 50ug | 199.2 EUR |
FCER1A Antibody |
|||
| GWB-MQ048C | GenWay Biotech | 50ug | Ask for price |
FCER1A Antibody |
|||
| GWB-MQ049D | GenWay Biotech | 50ug | Ask for price |
FCER1A Antibody |
|||
| E10-30466A | EnoGene | 100ul | 225 EUR |
|
Description: Available in various conjugation types. |
|||
FCER1A Antibody |
|||
| E10-30466P | EnoGene | 100ul | 225 EUR |
|
Description: Available in various conjugation types. |
|||
FCER1A Antibody |
|||
| E308995 | EnoGene | 200ul | 275 EUR |
|
Description: Available in various conjugation types. |
|||
FCER1A Antibody |
|||
| E91751 | EnoGene | 100ul | 255 EUR |
|
Description: Available in various conjugation types. |
|||
FCER1A Antibody |
|||
| MBS7044227-005mg | MyBiosource | 0.05mg | 190 EUR |
FCER1A Antibody |
|||
| MBS7044227-01mg | MyBiosource | 0.1mg | 270 EUR |
FCER1A Antibody |
|||
| MBS7044227-5x01mg | MyBiosource | 5x0.1mg | 1205 EUR |
FCER1A Antibody |
|||
| MBS9607249-01mL | MyBiosource | 0.1mL | 260 EUR |
FCER1A Antibody |
|||
| MBS9607249-02mL | MyBiosource | 0.2mL | 305 EUR |
FCER1A Antibody |
|||
| MBS9607249-5x02mL | MyBiosource | 5x0.2mL | 1220 EUR |
FCER1A Antibody |
|||
| MBS8501490-01mL | MyBiosource | 0.1mL | 325 EUR |
FCER1A Antibody |
|||
| MBS8501490-01mLAF405L | MyBiosource | 0.1mL(AF405L) | 565 EUR |
FCER1A Antibody |
|||
| MBS8501490-01mLAF405S | MyBiosource | 0.1mL(AF405S) | 565 EUR |
FCER1A Antibody |
|||
| MBS8501490-01mLAF610 | MyBiosource | 0.1mL(AF610) | 565 EUR |
FCER1A Antibody |
|||
| MBS8501490-01mLAF635 | MyBiosource | 0.1mL(AF635) | 565 EUR |
FCER1A Antibody |
|||
| MBS9414253-005mL | MyBiosource | 0.05mL | 300 EUR |
FCER1A Antibody |
|||
| MBS9414253-01mL | MyBiosource | 0.1mL | 390 EUR |
FCER1A Antibody |
|||
| MBS9414253-5x01mL | MyBiosource | 5x0.1mL | 1610 EUR |
FCER1A Antibody (PE) |
|||
| abx229408-100g | Abbexa | 100 µg | 75 EUR |
FCER1A Antibody (APC) |
|||
| abx229409-100g | Abbexa | 100 µg | 100 EUR |
FCER1A Antibody (FITC) |
|||
| abx229407-100g | Abbexa | 100 µg | 75 EUR |
FCER1A antibody - middle region |
|||
| MBS3207683-01mL | MyBiosource | 0.1mL | 455 EUR |
FCER1A antibody - middle region |
|||
| MBS3207683-5x01mL | MyBiosource | 5x0.1mL | 1995 EUR |
FCER1A Antibody, HRP conjugated |
|||
| 1-CSB-PA008532LB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against FCER1A. Recognizes FCER1A from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
FCER1A Antibody, HRP conjugated |
|||
| MBS7045141-005mg | MyBiosource | 0.05mg | 190 EUR |
FCER1A Antibody, HRP conjugated |
|||
| MBS7045141-01mg | MyBiosource | 0.1mg | 270 EUR |
FCER1A Antibody, HRP conjugated |
|||
| MBS7045141-5x01mg | MyBiosource | 5x0.1mg | 1205 EUR |
FCER1A Antibody, FITC conjugated |
|||
| 1-CSB-PA008532LC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against FCER1A. Recognizes FCER1A from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
FCER1A Antibody, FITC conjugated |
|||
| MBS7046165-005mg | MyBiosource | 0.05mg | 190 EUR |
FCER1A Antibody, FITC conjugated |
|||
| MBS7046165-01mg | MyBiosource | 0.1mg | 270 EUR |
FCER1A Antibody, FITC conjugated |
|||
| MBS7046165-5x01mg | MyBiosource | 5x0.1mg | 1205 EUR |
OALA03801-50UG - FCER1A Antibody |
|||
| OALA03801-50UG | Aviva Systems Biology | 50ug | 539 EUR |
OACA09377-50UG - FCER1A Antibody |
|||
| OACA09377-50UG | Aviva Systems Biology | 50ug | 179 EUR |
FCER1A Antibody, Biotin conjugated |
|||
| 1-CSB-PA008532LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against FCER1A. Recognizes FCER1A from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
FCER1A Antibody, Biotin conjugated |
|||
| MBS7046389-005mg | MyBiosource | 0.05mg | 190 EUR |
FCER1A Antibody, Biotin conjugated |
|||
| MBS7046389-01mg | MyBiosource | 0.1mg | 270 EUR |
FCER1A Antibody, Biotin conjugated |
|||
| MBS7046389-5x01mg | MyBiosource | 5x0.1mg | 1205 EUR |
OAAJ07067-100UL - FCER1A Antibody |
|||
| OAAJ07067-100UL | Aviva Systems Biology | 100uL | 319 EUR |
OACA09377-100UG - FCER1A Antibody |
|||
| OACA09377-100UG | Aviva Systems Biology | 100ug | 319 EUR |
FCER1A polyclonal antibody |
|||
| BS6605 | Bioworld Biotech | 50 ul | 358 EUR |
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
|||
FCER1A Polyclonal Antibody |
|||
| E-AB-91800-120uL | Elabscience Biotech | 120uL | 320 EUR |
|
Description: Unconjugated |
|||
FCER1A Polyclonal Antibody |
|||
| E-AB-91800-200uL | Elabscience Biotech | 200uL | 530 EUR |
|
Description: Unconjugated |
|||
FCER1A Polyclonal Antibody |
|||
| E-AB-91800-60uL | Elabscience Biotech | 60uL | 200 EUR |
|
Description: Unconjugated |
|||
FCER1A Polyclonal Antibody |
|||
| E-AB-91800-each | Elabscience Biotech | each | Ask for price |
|
Description: Unconjugated |
|||
FCER1A Conjugated Antibody |
|||
| C32415 | SAB | 100ul | 476.4 EUR |
FCER1A Polyclonal Antibody |
|||
| MBS126480-002mL | MyBiosource | 0.02mL | 200 EUR |
FCER1A Polyclonal Antibody |
|||
| MBS126480-005mL | MyBiosource | 0.05mL | 255 EUR |
FCER1A Polyclonal Antibody |
|||
| MBS126480-01mL | MyBiosource | 0.1mL | 345 EUR |
FCER1A Polyclonal Antibody |
|||
| MBS126480-02mL | MyBiosource | 0.2mL | 545 EUR |
FCER1A Polyclonal Antibody |
|||
| MBS126480-5x02mL | MyBiosource | 5x0.2mL | 2265 EUR |
FCER1A Conjugated Antibody |
|||
| MBS9443537-01mLAF350 | MyBiosource | 0.1mL(AF350) | 480 EUR |
FCER1A Conjugated Antibody |
|||
| MBS9443537-01mLAF405 | MyBiosource | 0.1mL(AF405) | 480 EUR |
FCER1A Conjugated Antibody |
|||
| MBS9443537-01mLAF488 | MyBiosource | 0.1mL(AF488) | 480 EUR |
FCER1A Conjugated Antibody |
|||
| MBS9443537-01mLAF555 | MyBiosource | 0.1mL(AF555) | 480 EUR |
FCER1A Conjugated Antibody |
|||
| MBS9443537-01mLBiotin | MyBiosource | 0.1mL(Biotin) | 480 EUR |
FCER1A antibody - N-terminal region |
|||
| MBS3207682-01mL | MyBiosource | 0.1mL | 455 EUR |
FCER1A antibody - N-terminal region |
|||
| MBS3207682-5x01mL | MyBiosource | 5x0.1mL | 1995 EUR |
Monoclonal FCER1A Antibody, Clone: 1F2A9 |
|||
| AMM03109G | Leading Biology | 0.1ml | 633.6 EUR |
|
Description: A Monoclonal antibody against Human FCER1A. The antibodies are raised in Mouse and are from clone 1F2A9. This antibody is applicable in WB, FC, E |
|||
Monoclonal FCER1A Antibody, Clone: 1F2A9 |
|||
| AMM03110G | Leading Biology | 0.1ml | 633.6 EUR |
|
Description: A Monoclonal antibody against Human FCER1A. The antibodies are raised in Mouse and are from clone 1F2A9. This antibody is applicable in WB, FC, E |
|||
Polyclonal FCER1A antibody - middle region |
|||
| APR00958G | Leading Biology | 0.05mg | 633.6 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FCER1A - middle region. This antibody is tested and proven to work in the following applications: |
|||
Polyclonal FCER1A antibody - N-terminal region |
|||
| APR00957G | Leading Biology | 0.05mg | 633.6 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FCER1A - N-terminal region. This antibody is tested and proven to work in the following applications: |
|||
ARP45205_P050-25UL - FCER1A Antibody - middle region |
|||
| ARP45205_P050-25UL | Aviva Systems Biology | 25ul | 99 EUR |
OAEB03398-100UG - FCER1A Antibody - middle region |
|||
| OAEB03398-100UG | Aviva Systems Biology | 100ug | 349 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| MBS8527730-01mL | MyBiosource | 0.1mL | 305 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| MBS8527730-01mLAF405L | MyBiosource | 0.1mL(AF405L) | 565 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| MBS8527730-01mLAF405S | MyBiosource | 0.1mL(AF405S) | 565 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| MBS8527730-01mLAF610 | MyBiosource | 0.1mL(AF610) | 565 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| MBS8527730-01mLAF635 | MyBiosource | 0.1mL(AF635) | 565 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| MBS8527731-01mL | MyBiosource | 0.1mL | 305 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| MBS8527731-01mLAF405L | MyBiosource | 0.1mL(AF405L) | 565 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| MBS8527731-01mLAF405S | MyBiosource | 0.1mL(AF405S) | 565 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| MBS8527731-01mLAF610 | MyBiosource | 0.1mL(AF610) | 565 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| MBS8527731-01mLAF635 | MyBiosource | 0.1mL(AF635) | 565 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| sAP-0976 | Angio Proteomie | 50ug | 270 EUR |
Mouse Monoclonal Antibody to FCER1A |
|||
| sAP-0977 | Angio Proteomie | 50ug | 270 EUR |
Fcer1a/ Rat Fcer1a ELISA Kit |
|||
| ELI-48496r | Lifescience Market | 96 Tests | 1063.2 EUR |
ARP45205_P050 - FCER1A antibody - middle region (ARP45205_P050) |
|||
| ARP45205_P050 | Aviva Systems Biology | 100ul | 389 EUR |
ARP45203_P050-25UL - FCER1A Antibody - N-terminal region |
|||
| ARP45203_P050-25UL | Aviva Systems Biology | 25ul | 99 EUR |
FCER1A |
|||
| CSB-CL008532HU | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
FCER1A |
|||
| E8EM1708-91 | EnoGene | 100ul | 275 EUR |
|
Description: Available in various conjugation types. |
|||
FCER1A |
|||
| MBS8565057-01mL | MyBiosource | 0.1mL | 345 EUR |
FCER1A |
|||
| MBS8565057-01mLAF405L | MyBiosource | 0.1mL(AF405L) | 565 EUR |
FCER1A |
|||
| MBS8565057-01mLAF405S | MyBiosource | 0.1mL(AF405S) | 565 EUR |
FCER1A |
|||
| MBS8565057-01mLAF610 | MyBiosource | 0.1mL(AF610) | 565 EUR |
FCER1A |
|||
| MBS8565057-01mLAF635 | MyBiosource | 0.1mL(AF635) | 565 EUR |
FCER1A |
|||
| MBS8561361-01mLAF405L | MyBiosource | 0.1mL(AF405L) | 565 EUR |
FCER1A |
|||
| MBS8561361-01mLAF405S | MyBiosource | 0.1mL(AF405S) | 565 EUR |
FCER1A |
|||
| MBS8561361-01mLAF610 | MyBiosource | 0.1mL(AF610) | 565 EUR |
FCER1A |
|||
| MBS8561361-01mLAF635 | MyBiosource | 0.1mL(AF635) | 565 EUR |
Neuroprotective Results of Casein-Derived Peptide Met-Lys-Professional (MKP) in a Hypertensive Mannequin
We’ve beforehand reported that casein hydrolysate, CH-3, from bovine milk and casein-derived tripeptide Met-Lys-Professional (MKP) has ACE inhibitory exercise and reduces blood strain. On this research, we investigated the therapeutic results of MKP in a hypertensive rat mannequin (7-week-old male SHRSP/Izm rats). For long run analysis, rats have been fed both a food regimen containing CH-Three or regular food regimen.
The survival charge of SHRSP rats was considerably improved by consumption of CH-Three for 181 days. For brief time period analysis, rats have been orally administered artificial tripeptide MKP or distilled water for Four weeks. MRI research demonstrated that hemorrhagic lesions have been noticed in two of 5 rats within the management group, whereas no hemorrhagic lesions have been noticed within the MKP group.
Volumetric evaluation utilizing MRI revealed that MKP administration inhibited atrophy of diencephalic areas. Histological examinations revealed that hemorrhage areas and astrogliosis within the hippocampus and cerebral cortex have been decrease within the MKP group than within the management group. Gene expression evaluation indicated that MKP administration diminished expression of genes associated to cerebral circulation insufficiency corresponding to immune responses (Cd74 and Prkcd), response to hypoxia (Ddit4, Apold1, and Prkcd), reactive oxygen species metabolic course of (Ddit4 and Pdk4), and apoptotic course of (Ddit4, Prkcd, and Sgk1), suggesting that MKP administration prevented cerebral ischemia related to hypertension.
As well as, some genes encoding responses to hormone stimulus (Fos, Dusp1, and Sik1) have been additionally downregulated. Serum aldosterone and corticosterone ranges have been additionally considerably decreased following MKP administration. The current research signifies that MKP reveals neuroprotective results in SHRSP rats by regulating cerebral circulation insufficiency and corticoid ranges. MKP administration could due to this fact be a possible therapeutic technique for hypertensive mind illnesses corresponding to cerebrovascular illness.
Antimicrobial Peptides as New Mixture Brokers in Most cancers Therapeutics: A Promising Protocol towards HT-29 Tumoral Spheroids
Antimicrobial peptides are molecules synthetized by a big number of organisms as an innate protection towards pathogens. These pure compounds have been recognized as promising alternate options to broadly used molecules to deal with infections and most cancers cells.
Antimicrobial peptides could possibly be seen as future chemotherapeutic alternate options, having the benefit of low propensity to drug resistance. On this research, we evaluated the effectivity of the antimicrobial peptide gramicidin A (GA) and the anticancer drug, doxorubicin (Doxo) towards the spheroids from colorectal most cancers cells (HT-29). The 2 medicine have been utilized individually towards HT-29 spheroids in addition to collectively to find out if they will act synergistically.
The spheroid evolution, cell viability, and ATP ranges have been monitored at 24 and 48 h after the utilized therapies. The outcomes present vital drops in cell viability and mobile ATP ranges for all of the experimental therapies. The simultaneous use of the 2 compounds (GA and Doxo) appears to trigger a synergistic impact towards the spheroids
Nop30 Blocking Peptide |
|||
| MBS823317-5x5mg | MyBiosource | 5x5mg | 1465 EUR |
Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401 |
|||
| 004-04 | PHOENIX PEPTIDE | 100 μg | 140.4 EUR |
Peptide T |
|||
| 057-01 | PHOENIX PEPTIDE | 5 mg | 140.4 EUR |
FGL Peptide |
|||
| 073-36 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
APK peptide |
|||
| 076-81 | PHOENIX PEPTIDE | 200 μg | 199.8 EUR |
NEF peptide |
|||
| 076-83 | PHOENIX PEPTIDE | 500 μg | 140.4 EUR |
SHA peptide |
|||
| 076-84 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
YSY peptide |
|||
| 076-86 | PHOENIX PEPTIDE | 100 μg | 230.04 EUR |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
| 024-57 | PHOENIX PEPTIDE | 200 μg | 86.4 EUR |
PSTAIR Peptide |
|||
| 070-61 | PHOENIX PEPTIDE | 500 μg | 129.6 EUR |
PGMtide Peptide |
|||
| 040-69 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Adjuvant Peptide |
|||
| 070-05 | PHOENIX PEPTIDE | 500 μg | 36.72 EUR |
Peptide-epsilon |
|||
| 058-22 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
Delicious Peptide |
|||
| 070-21 | PHOENIX PEPTIDE | 5 mg | 160.92 EUR |
proSex peptide (20-55) |
|||
| 040-30 | PHOENIX PEPTIDE | 100 μg | 355.32 EUR |
proSex peptide (28-55) |
|||
| 040-31 | PHOENIX PEPTIDE | 100 μg | 282.96 EUR |
proSex peptide (40-55) |
|||
| 040-32 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
| 007-60 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Peptide F-9 |
|||
| 038-06 | PHOENIX PEPTIDE | 200 μg | 58.32 EUR |
Sturgeon Peptide (137-158) |
|||
| 021-94 | PHOENIX PEPTIDE | 100 μg | 177.12 EUR |
NGR Peptide 1 |
|||
| 025-74 | PHOENIX PEPTIDE | 200 μg | 184.68 EUR |
Peptide Lv (Rat) |
|||
| 008-73 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
Anorexigenic Peptide |
|||
| 070-10 | PHOENIX PEPTIDE | 5 mg | 86.4 EUR |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
| 029-03 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
| 029-04 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
| 029-05 | PHOENIX PEPTIDE | 20 μg | 267.84 EUR |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
| 029-06 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
Bid BH3 peptide |
|||
| 025-87 | PHOENIX PEPTIDE | 1 mg | 170.64 EUR |
AF-16 Peptide |
|||
| 033-44 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Peptide Lv (Human) |
|||
| 008-71 | PHOENIX PEPTIDE | 100 μg | 405 EUR |
Peptide Lv (Mouse) |
|||
| 008-72 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
| 029-08 | PHOENIX PEPTIDE | 200 μg | 64.8 EUR |
ExE peptide M3mP6 |
|||
| 064-33 | PHOENIX PEPTIDE | 200 μg | 244.08 EUR |
Peptide B (Bovine) |
|||
| 024-56 | PHOENIX PEPTIDE | 200 μg | 81 EUR |
Peptide F (Bovine) |
|||
| 024-58 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
PLP Peptide (103-116) (Bovine) |
|||
| 070-14 | PHOENIX PEPTIDE | 5 mg | 140.4 EUR |
FMRF-Like Peptide |
|||
| 047-32 | PHOENIX PEPTIDE | 1 mg | 27 EUR |
Joining Peptide (Rat) |
|||
| 047-91 | PHOENIX PEPTIDE | 200 μg | 160.92 EUR |
NOP5/NOP58 Blocking Peptide |
|||
| 33R-5398 | Fitzgerald | 100 ug | 119 EUR |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NOP5/NOP58 antibody, catalog no. 70R-3412 |
|||
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
| 048-80 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
| 048-81 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
| 048-82 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Peptide T (4-8) |
|||
| 057-04 | PHOENIX PEPTIDE | 500 μg | 64.8 EUR |
Peptide T (5-8) |
|||
| 057-05 | PHOENIX PEPTIDE | 500 μg | 64.8 EUR |
Vasonatrin Peptide (VNP) |
|||
| 005-47 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Opioid Peptide Library |
|||
| L-002 | PHOENIX PEPTIDE | 58 peptides | 2691.36 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
| 064-01 | PHOENIX PEPTIDE | 200 μg | 108 EUR |
NOP58 Blocking Peptide |
|||
| DF13192-BP | Affbiotech | 1mg | 234 EUR |
NOP56 Blocking Peptide |
|||
| MBS8247999-1mg | MyBiosource | 1mg | 190 EUR |
NOP56 Blocking Peptide |
|||
| MBS8247999-5mg | MyBiosource | 5mg | 345 EUR |
NOP56 Blocking Peptide |
|||
| MBS8247999-5x5mg | MyBiosource | 5x5mg | 1465 EUR |
NOP58 Blocking Peptide |
|||
| MBS9621895-1mg | MyBiosource | 1mg | 380 EUR |
NOP58 Blocking Peptide |
|||
| MBS9621895-5x1mg | MyBiosource | 5x1mg | 1650 EUR |
NOP10 Blocking Peptide |
|||
| MBS9622423-1mg | MyBiosource | 1mg | 380 EUR |
NOP10 Blocking Peptide |
|||
| MBS9622423-5x1mg | MyBiosource | 5x1mg | 1650 EUR |
PGMtide Control Peptide |
|||
| 040-70 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Growth Blocking Peptide |
|||
| 046-92 | PHOENIX PEPTIDE | 100 μg | 255.96 EUR |
Neuron Specific Peptide |
|||
| 047-55 | PHOENIX PEPTIDE | 200 μg | 140.4 EUR |
Heparin Binding Peptide |
|||
| 025-47 | PHOENIX PEPTIDE | 500 μg | 102.6 EUR |
Gastrin Related Peptide |
|||
| 027-09 | PHOENIX PEPTIDE | 5 mg | 73.44 EUR |
Obesity Peptide Library |
|||
| L-003 | PHOENIX PEPTIDE | 160 peptides | 7267.32 EUR |
[D-Ala1]-Peptide T |
|||
| 057-02 | PHOENIX PEPTIDE | 5 mg | 282.96 EUR |
Peptide YY (PYY) (Human) |
|||
| 059-01 | PHOENIX PEPTIDE | 200 μg | 119.88 EUR |
Eledoisin Related Peptide |
|||
| 046-04 | PHOENIX PEPTIDE | 5 mg | 58.32 EUR |
proSex peptide (28-55) - EIA Kit |
|||
| EK-040-31 | PHOENIX PEPTIDE | 96 wells | 603.72 EUR |
Peptide F 1 (Lobster) |
|||
| 047-62 | PHOENIX PEPTIDE | 500 μg | 73.44 EUR |
Phosphate Acceptor Peptide |
|||
| 058-24 | PHOENIX PEPTIDE | 500 μg | 73.44 EUR |
Morphine Tolerance Peptide |
|||
| 050-13 | PHOENIX PEPTIDE | 1 mg | 102.6 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
| 064-07 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
| 047-39 | PHOENIX PEPTIDE | 200 μg | 444.96 EUR |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
| 047-40 | PHOENIX PEPTIDE | 500 μg | 214.92 EUR |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
| 047-42 | PHOENIX PEPTIDE | 200 μg | 444.96 EUR |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
| 047-43 | PHOENIX PEPTIDE | 500 μg | 214.92 EUR |
FGL Peptide - Cy3 Labeled |
|||
| FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | 672.84 EUR |
FGL Peptide - Cy5 Labeled |
|||
| FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | 756 EUR |
FGL Peptide - FAM Labeled |
|||
| FG-073-36A | PHOENIX PEPTIDE | 1 nmol | 405 EUR |
Pedal Peptide (Pep) (Aplysia) |
|||
| 047-61 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
ExE peptide M3mP6 mutant |
|||
| 064-35 | PHOENIX PEPTIDE | 200ug | 234.36 EUR |
ExE peptide M3mP6 mutant |
|||
| 064-37 | PHOENIX PEPTIDE | 200ug | 234.36 EUR |
AF-16 Peptide - Antibody |
|||
| H-033-44 | PHOENIX PEPTIDE | 100 μl | 336.96 EUR |
FGL Peptide - FITC Labeled |
|||
| FG-073-36B | PHOENIX PEPTIDE | 1 nmol | 405 EUR |
Schizophrenia Related Peptide |
|||
| 047-79 | PHOENIX PEPTIDE | 5 mg | 44.28 EUR |
Insulin B (22-25) Peptide |
|||
| 035-08 | PHOENIX PEPTIDE | 5 mg | 86.4 EUR |
Eosinophilotactic Peptide (AGSE) |
|||
| 070-28 | PHOENIX PEPTIDE | 5 mg | 27 EUR |
Eosinophilotactic Peptide (VGSE) |
|||
| 070-29 | PHOENIX PEPTIDE | 5 mg | 27 EUR |
Cell Penetrating ARF Peptide (26-44) |
|||
| 068-56 | PHOENIX PEPTIDE | 500 μg | 640.44 EUR |
Nop30 Antibody |
|||
| 20-abx008470 | Abbexa |
|
|
Nop30 antibody |
|||
| 70R-50659 | Fitzgerald | 100 ul | 242 EUR |
|
Description: Purified Polyclonal Nop30 antibody |
|||
Nop30 Antibody |
|||
| 2225-002mg | ProSci | 0.02 mg | 206.18 EUR |
|
Description: Nop30 Antibody: Apoptosis, also known as programmed cell death, plays major roles in development and normal tissue turnover in addition to tumor formation. Apoptosis is regulated by death domain (DD) and/or caspase recruitment domain (CARD) containing molecules and the caspase family of proteases. CARD domain containing cell death regulators include RAIDD, Apaf-1, caspase-9, and caspase-2. A novel CARD domain containing protein was recently identified and designated ARC for apoptosis repressor with CARD. An alternate splicing isoform of ARC was identified as Nop30. While ARC interacts with caspase-2 and -8 and suppresses apoptosis induced by cell death adapters FADD and TRADD and by cell death receptors Fas, TNFR-1 and DR3, Nop30 multimerizes and binds to the splicing factor SRp30c and may act to influence alternative splice site selection in vivo. The Nop30 antibody will not detect ARC protein. |
|||
Nop30 Antibody |
|||
| 2225-01mg | ProSci | 0.1 mg | 523.7 EUR |
|
Description: Nop30 Antibody: Apoptosis, also known as programmed cell death, plays major roles in development and normal tissue turnover in addition to tumor formation. Apoptosis is regulated by death domain (DD) and/or caspase recruitment domain (CARD) containing molecules and the caspase family of proteases. CARD domain containing cell death regulators include RAIDD, Apaf-1, caspase-9, and caspase-2. A novel CARD domain containing protein was recently identified and designated ARC for apoptosis repressor with CARD. An alternate splicing isoform of ARC was identified as Nop30. While ARC interacts with caspase-2 and -8 and suppresses apoptosis induced by cell death adapters FADD and TRADD and by cell death receptors Fas, TNFR-1 and DR3, Nop30 multimerizes and binds to the splicing factor SRp30c and may act to influence alternative splice site selection in vivo. The Nop30 antibody will not detect ARC protein. |
|||
Nop30 Antibody |
|||
| 24090 | SAB | 100ul | 479 EUR |
Nop30 Antibody |
|||
| 24090-100ul | SAB | 100ul | 468 EUR |
Nop30 Antibody |
|||
| 20-abx141839 | Abbexa |
|
|
Nop30 Antibody |
|||
| E38PA2340 | EnoGene | 100ul | 225 EUR |
|
Description: Available in various conjugation types. |
|||
Nop30 Antibody |
|||
| E38QA1337 | EnoGene | 100ug/100ul | 225 EUR |
Nop30 Antibody |
|||
| MBS5315278-01mL | MyBiosource | 0.1mL | 470 EUR |
Nop30 Antibody |
|||
| MBS5315278-5x01mL | MyBiosource | 5x0.1mL | 1955 EUR |
Nop30 Antibody |
|||
| MBS151174-01mg | MyBiosource | 0.1mg | 445 EUR |
Nop30 Antibody |
|||
| MBS151174-5x01mg | MyBiosource | 5x0.1mg | 1965 EUR |
Nop30 Antibody |
|||
| MBS8581240-01mL | MyBiosource | 0.1mL | 305 EUR |
Nop30 Antibody |
|||
| MBS8581240-01mLAF405L | MyBiosource | 0.1mL(AF405L) | 465 EUR |
Nop30 Antibody |
|||
| MBS8581240-01mLAF405S | MyBiosource | 0.1mL(AF405S) | 465 EUR |
Nop30 Antibody |
|||
| MBS8581240-01mLAF610 | MyBiosource | 0.1mL(AF610) | 465 EUR |
Nop30 Antibody |
|||
| MBS8581240-01mLAF635 | MyBiosource | 0.1mL(AF635) | 465 EUR |
Nop30 Antibody |
|||
| MBS9411181-01mL | MyBiosource | 0.1mL | 495 EUR |
Nop30 Antibody |
|||
| MBS9411181-5x01mL | MyBiosource | 5x0.1mL | 2075 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
| RK-064-01 | PHOENIX PEPTIDE | 125 tubes | 932.04 EUR |
FGL Peptide - Biotin Labeled |
|||
| B-073-36 | PHOENIX PEPTIDE | 20 μg | 405 EUR |
Peptide F (Bovine) - Antibody |
|||
| H-024-58 | PHOENIX PEPTIDE | 50 μl | 238.68 EUR |
Brain Peptide (Bees) Library |
|||
| L-007 | PHOENIX PEPTIDE | 51 peptides | 6456.24 EUR |
AAP40644-100UG - NOP56 Peptide |
|||
| AAP40644-100UG | Aviva Systems Biology | 100ug | 99 EUR |
AAP40645-100UG - NOP56 Peptide |
|||
| AAP40645-100UG | Aviva Systems Biology | 100ug | 99 EUR |
Gastrointestinal Peptide Library |
|||
| L-006 | PHOENIX PEPTIDE | 200 peptides | 7267.32 EUR |
Peptide R / CXCR4 Antagonist |
|||
| 030-25 | PHOENIX PEPTIDE | 200 μg | 203.04 EUR |
PGMtide Peptide - Cy3 Labeled |
|||
| FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | 925.56 EUR |
PGMtide Peptide - FAM Labeled |
|||
| FG-040-69A | PHOENIX PEPTIDE | 5 nmol | 537.84 EUR |
[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
| 033-34 | PHOENIX PEPTIDE | 100 μg | 177.12 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
| H-064-07 | PHOENIX PEPTIDE | 50 μl | 238.68 EUR |
[D-Ala1]-Peptide T amide |
|||
| 057-03 | PHOENIX PEPTIDE | 500 μg | 140.4 EUR |
Peptide F (Bovine) - RIA Kit |
|||
| RK-024-58 | PHOENIX PEPTIDE | 125 tubes | 932.04 EUR |
Calmodulin Binding Peptide 1 |
|||
| 070-17 | PHOENIX PEPTIDE | 20 μg | 214.92 EUR |
Catch-Relaxing Peptide (CARP) |
|||
| 047-20 | PHOENIX PEPTIDE | 1 mg | 199.8 EUR |
FGL Peptide - Rhodamine Labeled |
|||
| FR-073-36 | PHOENIX PEPTIDE | 1 nmol | 537.84 EUR |
Peptide-Depleted Plasma (Rat) |
|||
| MB-099-02 | PHOENIX PEPTIDE | 2 ml | 119.88 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
| RK-064-07 | PHOENIX PEPTIDE | 125 tubes | 932.04 EUR |
Glycogenolysis-Inhibiting Peptide |
|||
| 023-63 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
Anti-Inflammatory Peptide 1 |
|||
| 004-01 | PHOENIX PEPTIDE | 200 μg | 27 EUR |
Anti-Inflammatory Peptide 2 |
|||
| 004-02 | PHOENIX PEPTIDE | 200 μg | 27 EUR |
Anti-Inflammatory Peptide 3 |
|||
| 004-03 | PHOENIX PEPTIDE | 200 μg | 27 EUR |
Urokinase-Derived Peptide A6 |
|||
| 025-12 | PHOENIX PEPTIDE | 500 μg | 129.6 EUR |
PGMtide Peptide - Biotin Labeled |
|||
| B-040-69 | PHOENIX PEPTIDE | 20 μg | 537.84 EUR |
Peptide 34 / GPR-54 Agonist |
|||
| 048-94 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
FGL Peptide - I-125 Labeled |
|||
| T-073-36 | PHOENIX PEPTIDE | 10 μCi | 1145.88 EUR |
Peptide-Depleted Plasma (Human) |
|||
| MB-099-01 | PHOENIX PEPTIDE | 2 ml | 119.88 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
| FG-064-07A | PHOENIX PEPTIDE | 1 nmol | 336.96 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
| T-064-01 | PHOENIX PEPTIDE | 10 μCi | 1145.88 EUR |
F3 Peptide / HMGN2 Fragment 3 |
|||
| 004-12 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Myosin Kinase Inhibiting Peptide |
|||
| 058-20 | PHOENIX PEPTIDE | 500 μg | 50.76 EUR |
Antimicrobial Trp-rich peptide |
|||
| 004-05 | PHOENIX PEPTIDE | 100 μg | 140.4 EUR |
Fibronectin CS1 Peptide (EILDVPST) |
|||
| 025-20 | PHOENIX PEPTIDE | 500 μg | 86.4 EUR |
Peptide YY (PYY) (3-36) (Human) |
|||
| 059-02 | PHOENIX PEPTIDE | 200 μg | 102.6 EUR |
Peptide YY (PYY) (Human) - Antibody |
|||
| H-059-01 | PHOENIX PEPTIDE | 100 μl | 469.8 EUR |
PGMtide Peptide - Rhodamine Labeled |
|||
| FR-040-69 | PHOENIX PEPTIDE | 5 nmol | 604.8 EUR |
Anti-Angiogenic Peptide Library |
|||
| L-008A | PHOENIX PEPTIDE | 88 peptides | 6067.44 EUR |
NOP53 Peptide - C-terminal region |
|||
| MBS3241602-01mg | MyBiosource | 0.1mg | 180 EUR |
NOP53 Peptide - C-terminal region |
|||
| MBS3241602-5x01mg | MyBiosource | 5x0.1mg | 730 EUR |
NOP14 Peptide - N-terminal region |
|||
| MBS3244806-01mg | MyBiosource | 0.1mg | 180 EUR |
NOP14 Peptide - N-terminal region |
|||
| MBS3244806-5x01mg | MyBiosource | 5x0.1mg | 730 EUR |
NOP14 Peptide - N-terminal region |
|||
| MBS3244807-01mg | MyBiosource | 0.1mg | 180 EUR |
NOP14 Peptide - N-terminal region |
|||
| MBS3244807-5x01mg | MyBiosource | 5x0.1mg | 730 EUR |